Chapter 11: Capital Budgeting and Risk
50. MedChem has a capital structure of 60% equity and 40% debt and a current beta of 1.2. MedChem is
considering an investment project in a new line of business that has an expected internal rate of return of 16%.
The typical firm already in the line of business that MedChem is considering expanding into has a beta of 1.5
and a capital structure that has 55% debt and 45% equity. The marginal tax rate for all these firms, including
MedChem, is 40%. If the current risk-free rate is 7% and the expected market risk premium is 8%, should
MedChem expand into the new line? Assume that MedChem will retain its current capital structure.
a. expand if after-tax cost of debt is 11.5% or less
b. expand if after-tax cost of debt is 15% or less
c. expand if after-tax cost of debt is 10.4% or less
d. do not expand
51. American Biodyne (AB) is considering expanding into a new line of business. The expansion will require an
investment of $500,000 in new equipment. This equipment which will cost another $300,000 to install, will be
depreciated on a straight-line basis over an 8-year period to an estimated salvage value of zero. If the expansion
project is accepted, working capital will increase by $100,000 immediately. Revenues for the first 3 years are
forecasted at $650,000 per year and at $800,000 in years 4-8. Operating costs exclusive of depreciation are
expected to be $310,000 per year for 3 years and increase to $400,000 per year for the following 5 years. AB
has a marginal tax rate of 40% and its required rate of return for the project under consideration is 16%. If AB
assumes that the new equipment will have an actual market value of $50,000 at the end of the 8th year, should
the expansion be undertaken?
a. Yes, NPV = $275,114
b. Yes, NPV = $265,964
c. Yes, NPV = $302,934
d. Yes, NPV = $272,434